Durable Humoral and Cellular Immune Responses Following Ad26.COV2.S Vaccination for COVID-19

Interim immunogenicity and efficacy data for the Ad26.COV2.S vaccine for COVID-19 have recently been reported(1–3). We describe here the 8-month durability of humoral and cellular immune responses in 20 individuals who received one or two doses of 5×10(10) vp or 10(11) vp Ad26.COV2.S and in 5 partic...

Descripción completa

Detalles Bibliográficos
Autores principales: Barouch, Dan H., Stephenson, Kathryn E., Sadoff, Jerald, Yu, Jingyou, Chang, Aiquan, Gebre, Makda, McMahan, Katherine, Liu, Jinyan, Chandrashekar, Abishek, Patel, Shivani, Le Gars, Mathieu, de Groot, Anne Marit, Heerwegh, Dirk, Struyf, Frank, Douoguih, Macaya, van Hoof, Johan, Schuitemaker, Hanneke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8282116/
https://www.ncbi.nlm.nih.gov/pubmed/34268527
http://dx.doi.org/10.1101/2021.07.05.21259918
Descripción
Sumario:Interim immunogenicity and efficacy data for the Ad26.COV2.S vaccine for COVID-19 have recently been reported(1–3). We describe here the 8-month durability of humoral and cellular immune responses in 20 individuals who received one or two doses of 5×10(10) vp or 10(11) vp Ad26.COV2.S and in 5 participants who received placebo(2). We evaluated antibody and T cell responses on day 239, which was 8 months after the single-shot vaccine regimen (N=10) or 6 months after the two-shot vaccine regimen (N=10), although the present study was not powered to compare these regimens(3). We also report neutralizing antibody responses against the parental SARS-CoV-2 WA1/2020 strain as well as against the SARS-CoV-2 variants D614G, B.1.1.7 (alpha), B.1.617.1 (kappa), B.1.617.2 (delta), P.1 (gamma), B.1.429 (epsilon), and B.1.351 (beta).

Ejemplares similares